The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Mohamad MohtyThe Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discusses the value of minimal residual disease (MRD) in multiple myeloma (MM).
In this video, Prof. Mohty discusses the use of MRD status in the treatment of patients with MM, highlighting an abstract presented by Luciano Costa during the ASH meeting, that showed it is feasible to use MRD-status to drive therapeutic decisions. However, it is important to note this trial was not a prospective randomized phase III trial. Prof. Mothy also notes the value of PET scanning as demonstrated in the CASSIOPET trial, and that MRD testing cannot replace PET scanning, rather they are complimentary. Lastly, Prof. Mohty comments on the potential use of mass spectrometry to test MRD-status, removing the requirement for bone marrow sample and giving very precise information.
The value of MRD in multiple myeloma